# Marijuana Rescheduling Hearing Set For June 29th, 2026 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/marijuana-rescheduling-hearing-2026/ > **Published:** 2026-06-22T11:04:23-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:50:57-04:00 > **Clinical Summary:** Learn about the marijuana rescheduling hearing 2026 and its impact on federal cannabis research and clinical practice. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustrySafetyMental HealthAnxietyPain Why This Matters Rescheduling cannabis from Schedule I to Schedule III would remove federal research restrictions, enabling clinicians to conduct rigorous trials needed to establish evidence-based dosing, efficacy, and safety profiles for therapeutic applications. This reclassification would also facilitate banking relationships and insurance coverage for [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/), potentially improving patient access to standardized, regulated products rather than unvetted alternatives. Clinicians should monitor this regulatory shift as it directly impacts their ability to recommend cannabis with confidence grounded in clinical evidence rather than anecdotal reports. Clinical Summary The scheduled June 2026 hearing on rescheduling cannabis from Schedule I to Schedule III represents a pivotal moment for [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) that could substantially reshape clinical practice and research. Moving cannabis to Schedule III would remove current federal restrictions that severely limit [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/), potentially enabling larger, more rigorous trials that could establish evidence-based dosing regimens and optimal therapeutic uses across various conditions. Such rescheduling would also improve clinicians’ ability to access banking services, conduct federally-funded research, and participate in insurance billing, thereby reducing the current operational barriers that constrain [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) development and integration into mainstream healthcare. The expanded research opportunities could accelerate our understanding of [cannabis pharmacology](https://cedclinic.com/cannabis-tolerance-behavioral-models/), drug interactions, and long-term safety profiles, information that is currently limited by regulatory constraints. Clinicians should monitor this hearing’s outcome, as rescheduling could significantly alter the evidence landscape and regulatory environment within which they counsel patients and consider cannabis as a therapeutic option. Dr. Caplan’s Take “What we really need from rescheduling is the removal of research barriers that have frankly hamstrung our ability to generate rigorous clinical evidence for two decades. Right now I’m treating patients with cannabis, but I’m doing so largely on clinical observation and patient report rather than the kind of controlled trials that would typically inform my prescribing for any other medication, and that’s a genuine limitation we need to fix.” Clinical Perspective 🔬 The proposed rescheduling of cannabis from Schedule I to Schedule III represents a significant regulatory shift that could meaningfully expand the evidence base for clinical decision-making, particularly by removing federal barriers to research and improving banking relationships for legitimate dispensaries. However, clinicians should remain cautious about assuming that rescheduling automatically validates cannabis as a mainstream therapeutic agent, since regulatory status and clinical efficacy are distinct domains; existing evidence for cannabis remains mixed and limited for most indications outside of specific seizure disorders and chemotherapy-related nausea. The expanded research opportunities that rescheduling may facilitate could eventually clarify which patient populations benefit from cannabis, what dosing regimens are safe and effective, and how cannabis interacts with commonly prescribed medications. In practice, clinicians should continue to approach cannabis inquiries and recommendations with the same rigor applied to other medications—obtaining detailed use histories, discussing evidence-based alternatives, and acknowledging gaps in our knowledge 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Marijuana%20Rescheduling%20Hearing%20Set%20For%20June%2029th%2C%202026%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D63946)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D63946)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Marijuana%20Rescheduling%20Hearing%20Set%20For%20June%2029th%2C%202026%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D63946)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - In the Mix: 37 More Articles — June 20, 2026 - [This Week in Cannabis: June 19, 2026](https://cedclinic.com/cannabis-use-disorder-stigma-june-19-2026/) - [In the Mix: 20 More Articles — June 19, 2026](https://cedclinic.com/mixed-cannabis-industry-articles-june-19-2026/) 📰 Source: [https://respectmyregion.com/marijuana-rescheduling-hearing-june-29-2026/](https://respectmyregion.com/marijuana-rescheduling-hearing-june-29-2026/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Federal Marijuana reclassification could reshape medical research and cannabis industry](https://cedclinic.com/federal-marijuana-rescheduling-medical-research-clinical-impact/) Explore how federal marijuana rescheduling may impact [medical research](https://cedclinic.com/cb2-receptor-agonist-parkinsons/) and the cannabis industry landscape. [Read More](https://cedclinic.com/federal-marijuana-rescheduling-medical-research-clinical-impact/) [DOJ Moves to Loosen Cannabis Restrictions, Signals Shift Toward Rescheduling](https://cedclinic.com/doj-cannabis-policy-changes-shift-toward-rescheduling/) Understand the Department of Justice’s recent actions signaling a shift toward cannabis rescheduling. [Learn More](https://cedclinic.com/doj-cannabis-policy-changes-shift-toward-rescheduling/) [DEA Judge Issues Order Laying Out Process For Marijuana Rescheduling Hearing Starting …](https://cedclinic.com/dea-marijuana-rescheduling-procedural-order-hearing/) Details on the DEA judge’s order outlining the marijuana rescheduling hearing process starting in 2026. [Discover Details](https://cedclinic.com/dea-marijuana-rescheduling-procedural-order-hearing/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).